Signs deal for exclusive marketing and distribution of the only US FDA approved inhaled insulin
Cipla has entered into an exclusive marketing and distribution agreement with US-based MannKind Corporation for Afrezza in India. It is the only USFDA approved inhaled insulin available for patients suffering from diabetes.
“Cipla is committed to providing access to innovative medicines and newer drug delivery systems to the patients. Afrezza, an inhaled insulin, is a cutting-edge product which will increase patient convenience,” said Umang Vohra, MD & Global CEO, Cipla.
“The innovative drug delivery system will revolutionise the diabetic care in India. This partnership with MannKind is another step from Cipla to cater to the unmet needs of the patients,” states Michael Castagna, CEO, MannKind.
“This agreement with Cipla, our second international partnership agreement for Afrezza, extends the potential opportunity for approximately one out of four people of the worldwide population with diabetes to manage their disease with our novel mealtime insulin, when combined with our earlier agreement in Brazil and our own efforts in the US.”
Under the agreement, Cipla will be responsible for obtaining regulatory approvals to distribute Afrezza in India, including approval from the Drug Controller General of India (DCGI). Cipla will also be responsible for all marketing and sales activities of Afrezza in India. MannKind is responsible for supplying Afrezza to Cipla.